Study suggests improvement in overall survival of ovarian cancer with olaparib

Study results suggest an improvement in overall survival (OS) for patients with ovarian cancer treated with olaparib (Lynparza) maintenance therapy following platinum-based chemotherapy.  The update from Study 19 was presented  at the American Society of Clinical Oncology (ASCO) congress in Chicago. This comes after olaparib was made available to NHS patients in England and Wales from 27th April, for the treatment of women with platinum-sensitive relapsed (PSR) BRCA-mutated (BRCAm) high-grade serous ovarian cancer who have had three or more courses of platinum-based chemotherapy.  Olaparib received European Marketing Authorisation for platinum-sensitive relapsed (PSR) BRCA-mutated (BRCAm) high-grade serous ovarian cancer patients, who have had